MAP1LC3A and Parkinson disease: In humans, it has been reported that the majority of Lewy bodies (~80%) composed of α-syuclein in the SNpc of PD patients were strongly immonoreactive for LC3 (24), and similar observation for LC3 immunoreactivity was observed in Lewy bodies of dementia with Lewy bodies (DLB) patients (57).